350 related articles for article (PubMed ID: 28831696)
1. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD.
Derks-Smeets IAP; van Tilborg TC; van Montfoort A; Smits L; Torrance HL; Meijer-Hoogeveen M; Broekmans F; Dreesen JCFM; Paulussen ADC; Tjan-Heijnen VCG; Homminga I; van den Berg MMJ; Ausems MGEM; de Rycke M; de Die-Smulders CEM; Verpoest W; van Golde R
J Assist Reprod Genet; 2017 Nov; 34(11):1475-1482. PubMed ID: 28831696
[TBL] [Abstract][Full Text] [Related]
2. BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles.
Shapira M; Raanani H; Feldman B; Srebnik N; Dereck-Haim S; Manela D; Brenghausen M; Geva-Lerner L; Friedman E; Levi-Lahad E; Goldberg D; Perri T; Eldar-Geva T; Meirow D
Fertil Steril; 2015 Nov; 104(5):1162-7. PubMed ID: 26335130
[TBL] [Abstract][Full Text] [Related]
3. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation.
Gunnala V; Fields J; Irani M; D'Angelo D; Xu K; Schattman G; Rosenwaks Z
Fertil Steril; 2019 Feb; 111(2):363-371. PubMed ID: 30527950
[TBL] [Abstract][Full Text] [Related]
4. The ovarian response in fragile X patients and premutation carriers undergoing IVF-PGD: reappraisal.
Avraham S; Almog B; Reches A; Zakar L; Malcov M; Sokolov A; Alpern S; Azem F
Hum Reprod; 2017 Jul; 32(7):1508-1511. PubMed ID: 28472405
[TBL] [Abstract][Full Text] [Related]
5. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro.
Grynberg M; Dagher Hayeck B; Papanikolaou EG; Sifer C; Sermondade N; Sonigo C
Hum Reprod; 2019 Feb; 34(2):374-379. PubMed ID: 30561604
[TBL] [Abstract][Full Text] [Related]
6. Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer.
Porcu E; Cillo GM; Cipriani L; Sacilotto F; Notarangelo L; Damiano G; Dirodi M; Roncarati I
J Assist Reprod Genet; 2020 Mar; 37(3):709-715. PubMed ID: 31872386
[TBL] [Abstract][Full Text] [Related]
7. Ovarian reserve and PGD treatment outcome in women with myotonic dystrophy.
Srebnik N; Margalioth EJ; Rabinowitz R; Varshaver I; Altarescu G; Renbaum P; Levi-Lahad E; Weintraub A; Eldar-Geva T
Reprod Biomed Online; 2014 Jul; 29(1):94-101. PubMed ID: 24813161
[TBL] [Abstract][Full Text] [Related]
8. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
9. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
10. Do BRCA1 and BRCA2 gene mutation carriers have a reduced ovarian reserve? Protocol for a prospective observational study.
Winship AL; Willson C; Hansen KR; Hutt KJ; Hickey M
BMJ Open; 2019 Nov; 9(11):e033810. PubMed ID: 31772111
[TBL] [Abstract][Full Text] [Related]
11. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial.
Youssef MA; van Wely M; Al-Inany H; Madani T; Jahangiri N; Khodabakhshi S; Alhalabi M; Akhondi M; Ansaripour S; Tokhmechy R; Zarandi L; Rizk A; El-Mohamedy M; Shaeer E; Khattab M; Mochtar MH; van der Veen F
Hum Reprod; 2017 Jan; 32(1):112-118. PubMed ID: 27836979
[TBL] [Abstract][Full Text] [Related]
12. The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status.
C E DK; C VTT; J C EM; G W M LE; Irene H; Mariette G; J T VGR; Willem V; D LK; J M BF; M E BA
Reprod Sci; 2023 Jan; 30(1):270-282. PubMed ID: 35705781
[TBL] [Abstract][Full Text] [Related]
13. Uptake of Preimplantation Genetic Diagnosis in Female BRCA1 and BRCA2 Mutation Carriers.
Mor P; Brennenstuhl S; Metcalfe KA
J Genet Couns; 2018 Dec; 27(6):1386-1394. PubMed ID: 29858758
[TBL] [Abstract][Full Text] [Related]
14. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
15. Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors.
Derks-Smeets IA; de Die-Smulders CE; Mackens S; van Golde R; Paulussen AD; Dreesen J; Tournaye H; Verdyck P; Tjan-Heijnen VC; Meijer-Hoogeveen M; De Greve J; Geraedts J; De Rycke M; Bonduelle M; Verpoest WM
Breast Cancer Res Treat; 2014 Jun; 145(3):673-81. PubMed ID: 24748567
[TBL] [Abstract][Full Text] [Related]
16. Assessment of ovarian reserve and reproductive outcomes in
Ponce J; Fernandez-Gonzalez S; Calvo I; Climent M; Peñafiel J; Feliubadaló L; Teulé A; Lázaro C; Brunet JM; Candás-Estébanez B; Durán Retamal M
Int J Gynecol Cancer; 2020 Jan; 30(1):83-88. PubMed ID: 31780568
[TBL] [Abstract][Full Text] [Related]
17. PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers.
Drüsedau M; Dreesen JC; Derks-Smeets I; Coonen E; van Golde R; van Echten-Arends J; Kastrop PM; Blok MJ; Gómez-García E; Geraedts JP; Smeets HJ; de Die-Smulders CE; Paulussen AD
Eur J Hum Genet; 2013 Dec; 21(12):1361-8. PubMed ID: 23531862
[TBL] [Abstract][Full Text] [Related]
18. Luteal-phase ovarian stimulation increases the number of mature oocytes in older women with severe diminished ovarian reserve.
Rashtian J; Zhang J
Syst Biol Reprod Med; 2018 Jun; 64(3):216-219. PubMed ID: 29564925
[TBL] [Abstract][Full Text] [Related]
19. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin Releasing Hormone Agonists or Antagonists for Preimplantation Genetic Diagnosis (PGD)? A Prospective Randomised Trial.
Verpoest W; De Vos A; De Rycke M; Parikh S; Staessen C; Tournaye H; De Vos M; Vloeberghs V; Blockeel C
Curr Pharm Biotechnol; 2017 Nov; 18(8):622-627. PubMed ID: 28786358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
